Abstract
Advanced glycation end product (AGE) and receptor (RAGE) axis play a central role in the pathogenesis of diabetic vascular complications. Since peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have been reported to reduce RAGE gene expression and subsequently suppress the downstream signalings in human umbilical vein endothelial cells (HUVECs), we examined here whether telmisartan, a unique angiotensin II type 1 receptor blocker with PPAR-γ agonistic activity, could inhibit the AGE-induced up-regulation of plasminogen activator inhibitor-1 (PAI-1) mRNA levels in HUVECs by suppressing RAGE gene expression. Telmisartan completely blocked the AGE-induced RAGE gene up-regulation in HUVECs, which was partly prevented by GW9662, an inhibitor of PPAR-γ. Further, telmisartan was also found to inhibit up-regulation of mRNA levels for PAI-1 in AGE-exposed HUVECs, which was completely prevented by GW9662. These results suggest that telmisartan inhibits the AGE-induced PAI-1 gene induction in HUVECs by down-regulating RAGE expression via PPAR-γ activation. Our present study suggests that telmisartan works as an anti-thrombogenic agent against AGEs, which may play a protective role against vascular complications in diabetes.
Keywords: AGEs, RAGE, Telmisartan, PAI-1, PPAR-γ
Letters in Drug Design & Discovery
Title: Telmisartan Blocks Advanced Glycation End Product (AGE)-Induced Plasminogen Activator Inhibitor-1 (PAI-1) Gene Expression in Endothelial Cells via Activation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ )
Volume: 5 Issue: 8
Author(s): Takanori Matsui, Kazuo Nakamura, Masayoshi Takeuchi and Sho-ichi Yamagishi
Affiliation:
Keywords: AGEs, RAGE, Telmisartan, PAI-1, PPAR-γ
Abstract: Advanced glycation end product (AGE) and receptor (RAGE) axis play a central role in the pathogenesis of diabetic vascular complications. Since peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have been reported to reduce RAGE gene expression and subsequently suppress the downstream signalings in human umbilical vein endothelial cells (HUVECs), we examined here whether telmisartan, a unique angiotensin II type 1 receptor blocker with PPAR-γ agonistic activity, could inhibit the AGE-induced up-regulation of plasminogen activator inhibitor-1 (PAI-1) mRNA levels in HUVECs by suppressing RAGE gene expression. Telmisartan completely blocked the AGE-induced RAGE gene up-regulation in HUVECs, which was partly prevented by GW9662, an inhibitor of PPAR-γ. Further, telmisartan was also found to inhibit up-regulation of mRNA levels for PAI-1 in AGE-exposed HUVECs, which was completely prevented by GW9662. These results suggest that telmisartan inhibits the AGE-induced PAI-1 gene induction in HUVECs by down-regulating RAGE expression via PPAR-γ activation. Our present study suggests that telmisartan works as an anti-thrombogenic agent against AGEs, which may play a protective role against vascular complications in diabetes.
Export Options
About this article
Cite this article as:
Matsui Takanori, Nakamura Kazuo, Takeuchi Masayoshi and Yamagishi Sho-ichi, Telmisartan Blocks Advanced Glycation End Product (AGE)-Induced Plasminogen Activator Inhibitor-1 (PAI-1) Gene Expression in Endothelial Cells via Activation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ ), Letters in Drug Design & Discovery 2008; 5 (8) . https://dx.doi.org/10.2174/157018008786898590
DOI https://dx.doi.org/10.2174/157018008786898590 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Relationships of Birthweight and Postnatal Growth with Metabolic Risk Factors in Junior School Children in Korea
Current Hypertension Reviews Risk Scores for Patients with Chest Pain: Evaluation in the Emergency Department
Current Cardiology Reviews Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Catecholamines, Sympathetic Innervation and Immunity: Role in Experimental and Rheumatoid Arthritis
Letters in Drug Design & Discovery Magnetic Field-Assisted Gene Delivery: Achievements and Therapeutic Potential
Current Gene Therapy Advanced In Silico Approaches for Drug Discovery: Mining Information from Multiple Biological and Chemical Data Through mtk- QSBER and pt-QSPR Strategies
Current Medicinal Chemistry Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?
Current Pharmaceutical Design Role of Heme Oxygenases in Cardiovascular Syndromes and Co-morbidities
Current Pharmaceutical Design Bio Molecular Considerations in Major Depression and Ischemic Cardiovascular Disease
Central Nervous System Agents in Medicinal Chemistry Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design Biogenic Peptides and Their Potential Use
Current Pharmaceutical Design Saving the Ischemic Penumbra: Potential Role for Statins and Phosphodiesterase Inhibitors
Current Vascular Pharmacology An Experimental and Theoretical Approach to Understand Fever, DENF & its Cure
Infectious Disorders - Drug Targets Nuclear Receptors as Potential Targets for Modulating Reverse Cholesterol Transport
Current Topics in Medicinal Chemistry Copper as a Biocidal Tool
Current Medicinal Chemistry Incidence and Prevalence of Hypothyroidism in Patients Affected by Chronic Heart Failure: Role of Amiodarone
Endocrine, Metabolic & Immune Disorders - Drug Targets Arrhythmias and Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design Ethanol Metabolism and Effects: Nitric Oxide and its Interaction
Current Clinical Pharmacology Antiplatelet Therapy in the Prevention of Coronary Syndromes: Mode of Action, Benefits, Drawbacks
Cardiovascular & Hematological Agents in Medicinal Chemistry Access to Medicines and the Safety of the People
Reviews on Recent Clinical Trials